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High Density Lipoproteins Inhibit 
Oxidative Stress-Induced Prostate 
Cancer Cell Proliferation
Massimiliano Ruscica  1, Margherita Botta1, Nicola Ferri2, Eleonora Giorgio3, Chiara Macchi1, 
Guido Franceschini3, Paolo Magni1, Laura Calabresi3 & Monica Gomaraschi3
Recent evidence suggests that oxidative stress can play a role in the pathogenesis and the progression 
of prostate cancer (PCa). Reactive oxygen species (ROS) generation is higher in PCa cells compared to 
normal prostate epithelial cells and this increase is proportional to the aggressiveness of the phenotype. 
Since high density lipoproteins (HDL) are known to exert antioxidant activities, their ability to reduce 
ROS levels and the consequent impact on cell proliferation was tested in normal and PCa cell lines. 
HDL significantly reduced basal and H2O2-induced oxidative stress in normal, androgen receptor (AR)-
positive and AR-null PCa cell lines. AR, scavenger receptor BI and ATP binding cassette G1 transporter 
were not involved. In addition, HDL completely blunted H2O2-induced increase of cell proliferation, 
through their capacity to prevent the H2O2-induced shift of cell cycle distribution from G0/G1 towards 
G2/M phase. Synthetic HDL, made of the two main components of plasma-derived HDL (apoA-I and 
phosphatidylcholine) and which are under clinical development as anti-atherosclerotic agents, retained 
the ability of HDL to inhibit ROS production in PCa cells. Collectively, HDL antioxidant activity limits cell 
proliferation induced by ROS in AR-positive and AR-null PCa cell lines, thus supporting a possible role of 
HDL against PCa progression.
In almost all Western countries, prostate cancer (PCa) is the most commonly diagnosed cancer and the second 
leading cause of cancer-related death in men1. Since the prostate is an androgen-dependent organ, PCa develop-
ment is tightly associated with the presence of androgens and the activation of the androgen receptor (AR)2. Thus, 
AR is considered the most relevant target to control the growth and dissemination of PCa, with androgen depri-
vation (ADT) representing the backbone of the therapy for locally advanced and metastatic PCa after failure of 
localized treatments3. However, after initial effective response to ADT, PCa may develop into a castration-resistant 
phenotype (CRPC) despite low levels of circulating androgens4. In some cases, CRPC bypasses the requirements 
for AR signalling, while in others it retains its dependence on AR signalling as primary oncogenic driver5. To date, 
CRPC has few therapeutic options resulting only in a limited survival prolongation. Thus, novel strategies that 
could have direct cytotoxic effects on tumour cells or that could modify cell biology, making tumour cells more 
sensitive to the action of classical cytotoxic agents are required.
Recent evidence suggests that oxidative stress can play a role in the pathogenesis and the progression of PCa6. 
Oxidative stress occurs when the balance between the production of pro-oxidant molecules, as reactive oxy-
gen species (ROS), and their neutralization by detoxifying systems is lost. ROS are a heterogeneous group of 
highly reactive ions and molecules derived from molecular oxygen, including superoxide anion, hydroxyl radi-
cals, hydrogen peroxide and singlet oxygen7. ROS are normally generated within cell mitochondria, peroxisomes 
and microsomes; indeed, they are a by-product of normal mitochondrial respiration and of other enzymes as 
NADPH oxidase, xanthine oxidase and lipoxygenases7. Interestingly, ROS generation is higher in PCa cells than 
in normal prostate epithelial cells and this increment is proportional to the aggressiveness of the phenotype8. In 
addition, exogenous sources of ROS can be present in tumour microenvironment as xenobiotics or infiltrating 
inflammatory cells9. Indeed, resident immune cells, as lymphocytes, mast cells and macrophages, or those infil-
trating during an inflammatory event, utilize ROS and pro-oxidant enzymes to attack and neutralize a foreign 
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intruder10. PCa promotion and progression by oxidative stress are likely due to ROS reactivity towards key cellu-
lar components as nucleic acids, proteins and lipids. ROS can directly attack DNA causing single or double strand 
breaks as well as pyrimidine and purine lesions, both of which can affect the integrity of the genome and genomic 
instability11. In addition, ROS may cause epigenetic alterations, as DNA methylation patterns, possibly leading 
to the activation of oncogenes and/or the inhibition of tumour-suppressor genes11. ROS can also affect several 
signalling pathways mediating cell proliferation and differentiation, invasion and angiogenesis; for example, ROS 
were shown to activate the MAPK and PI3K/Akt pathways, to promote the production of prostaglandin E2 and 
of matrix metalloproteinases12,13.
High density lipoproteins (HDL) are a heterogeneous family of lipoproteins whose anti-atherosclerotic prop-
erties are well recognized14. Atheroprotection by HDL is related to their capacity to promote the removal of 
cholesterol from peripheral cells and its transport to the liver for excretion through the bile among the so-called 
reverse cholesterol transport15. In addition, HDL display anti-inflammatory and antioxidant activities that can 
contribute to their atheroprotective effects16. Many HDL activities are mediated by their interaction with differ-
ent transmembrane proteins, as the transporters ATP-binding cassette A1 and G1 and the scavenger receptor 
type BI15,16. Antioxidant properties of HDL are mainly due to: (i) their ability to uptake oxidized lipids from cell 
membranes and other lipoproteins, (ii) the presence on HDL of antioxidant enzymes as paraoxonase (PON-1), 
lecithin:cholesterol acyltransferase (LCAT) and platelet-activating factor acetylhydrolase, and (iii) their main pro-
tein components, apolipoproteins A-I and A-II, which can participate to redox reactions undergoing oxidation 
on their methionine residues14. HDL purified from human plasma are unsuitable for drug development, because 
of safety concerns, problems related to large-scale production and HDL heterogeneity17. These limitations can 
be overcome by preparing synthetic HDL (sHDL), discoidal particles made with a purified apolipoprotein and 
synthetic phospholipids; sHDL have been shown to retain several atheroprotective activities of plasma-derived 
HDL in vitro and in vivo and are currently under development as anti-atherosclerotic agents18.
Few and inconclusive studies addressed the relationship between plasma levels of HDL-C and the risk or prog-
nosis of PCa, while contrasting data have been published on the effect of HDL on the proliferation of PCa cell lines19. 
In the present study, we investigated the ability of HDL to reduce oxidative stress in PCa cells and the consequent 
impact on cell proliferation. To address tumour heterogeneity composed of cells with various degree of transforma-
tion, experiments were performed on normal prostate epithelial cells, AR-positive and AR-null PCa cell lines.
Results
Characterization of isolated HDL. Proteins accounted for about 43% of total HDL mass; phospholipids 
and cholesteryl esters represented most of the HDL lipids, with minor amounts of unesterified cholesterol and tri-
glycerides (Table S1)20. HDL protein fraction was composed by 78% of apoA-I and by 18% of apoA-II (Table S1). 
Regarding antioxidant enzymes carried by HDL, LCAT concentration was 35.2 ± 3.1 μg/mg of HDL protein, but 
no LCAT activity could be detected in isolated HDL. PON-1 activity in isolated HDL was 16.3 ± 3.6 nmol/min/
mg of protein; this value is less than 5% of the normal activity, as assessed in our laboratory on plasma samples 
from control subjects (352.3 ± 24.5 nmol/min/ml).
HDL reduced basal and H2O2-induced oxidative stress in LNCaP and PC-3 cells. Consistent with 
previous findings8, basal oxidative stress was significantly higher in PCa cell lines compared to normal prostate 
epithelial cells and the observed increase was proportional to the aggressiveness of the phenotype. Indeed, basal 
ROS level was 1.4 fold higher in LNCaP and 2.6 fold higher in PC-3 compared to that observed in PNT2 cells 
(Fig. S1).
Short- or long-term exposure to HDL reduced basal oxidative stress in LNCaP. Indeed, the incubation of 
LNCaP with HDL significantly decreased basal ROS level when given overnight (−28%) or only for 1 h before 
ROS detection (−27%, Fig. 1a). HDL were also able to reduce basal oxidative stress in PC-3 cells when given 1 h 
before ROS detection (−31%), but not for a longer incubation, likely as a consequence of the higher ROS produc-
tion in this cell type (Fig. 1b).
The ability of HDL to inhibit ROS production was also tested in cells stimulated with H2O2 for 1 h, in order 
to mimic a pro-oxidant environment. In LNCaP, H2O2 induced a 1.6-fold increase in basal ROS production, but 
this rise was completely blunted when cells were co-incubated with HDL (Fig. 1a). Interestingly, when HDL were 
added overnight or only for 1 h and then removed before H2O2 stimulation, ROS increase was again completely 
blunted. The anti-oxidant effect of HDL was concentration-dependent and 0.5 mg of protein/ml was the lowest 
concentration that significantly reduced ROS levels in H2O2-stimulated cells (Fig. S2). HDL were also able to exert 
their antioxidant effects on PC-3 cells: the 1.3-fold increment in ROS production induced by H2O2 was prevented 
by all treatments with HDL (Fig. 1b). Similar results were obtained with the normal prostate epithelial cell line 
PNT2 (Fig. S4).
AR activation was not involved in HDL antioxidant effect. The AR antagonist bicalutamide was 
used to disclose the role of AR signalling in mediating ROS production and HDL antioxidant effect in LNCaP. 
Overnight incubation with bicalutamide did not modify ROS increase after H2O2 challenge; indeed, ROS levels in 
cells pre-treated with bicalutamide and then stimulated with H2O2 for 1 h were comparable to those of untreated 
H2O2-stimulated cells (Fig. 2). HDL retained their antioxidant effect on H2O2-stimulated cells even in the pres-
ence of bicalutamide. Indeed, when LNCaP were pre-treated with bicalutamide and then stimulated with H2O2, 
HDL were able to significantly reduce ROS levels as an o/n pre-treatment or as a co-incubation with H2O2 (Fig. 2).
HDL antioxidant effect was not mediated by ABCG1 and SR-BI or by the modulation of cell 
cholesterol content. First, LNCaP and PC-3 cells were tested to evaluate altered protein expression of the 
transporters ABCA1 and ABCG1, and of the receptor SR-BI when compared to the normal prostate epithelial 
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cell line PNT2 (Fig. 3). ABCA1 showed a very low expression in PNT2 cells and a further decrease was evident 
in both PCa cell lines (−68% in LNCaP and −81% in PC-3). ABCG1 was almost undetectable in PNT2 cells, but 
a significant increase was observed in PCa cell lines; in particular, a 2.8 fold increase in LNCaP and a 5.8 fold 
increase in PC-3 were detected. SR-BI was well expressed in PNT2 cells and no significant changes were observed 
in the two PCa cell lines.
The possible role of the SR-BI receptor and of the ABCG1 transporter in mediating HDL antioxidant effect 
was disclosed through RNA interference experiments in PC-3 cells. The treatment with specific siRNAs caused 
a marked inhibition of SR-BI and ABCG1 protein expression; indeed, SR-BI protein expression was reduced by 
77.0 ± 8.9% and ABCG1 by 76.0 ± 8.3% (Fig. 4). The severe reduction of SR-BI expression affected neither the 
extent of ROS levels after H2O2 treatment, nor the antioxidant effect of HDL. Similar results were obtained when 
ABCG1 was silenced (Fig. 4). Being ABCA1 almost undetectable in tumour cells, silencing experiments targeting 
this transporter were not performed.
To further exclude that the antioxidant effect of HDL was mediated by the modulation of cell cholesterol 
content, experiments were repeated after cholesterol loading by LDL or depletion by βMCD. LDL increased 
cell cholesterol by 43.7 ± 7.6% in LNCaP and by 52.8 ± 22.7% in PC-3, while βMCD caused a reduction of 
19.9 ± 1.4% in LNCaP and of 22.2 ± 8.8% in PC-3. However, these changes of cell cholesterol did not affect basal 
or H2O2-stimulated ROS levels in both cell lines; in addition, HDL antioxidant effect was not altered by previous 
treatment with LDL or βMCD (Fig. S3).
HDL inhibited H2O2-induced cell proliferation. To mimic a chronic low-grade pro-oxidant environ-
ment, LNCaP were exposed to 5 µM H2O2 for 72 h; this treatment resulted in a significant increase of cell count, 
which raised by 25.3% (Fig. 5a). The co-incubation with HDL significantly reduced H2O2-mediated rise of cell 
count by 23.1%, bringing cell proliferation back to values of untreated cells (Fig. 5a). Similarly, H2O2 stimulated 
PC-3 cell growth by 29.7%, an effect completely blunted by the co-incubation with HDL (−36.9% vs H2O2) 
Figure 1. HDL reduced ROS production in LNCaP and PC-3 cell lines. LNCaP (Panel a) and PC-3 cells (Panel 
b) were pre-treated overnight (o/n) or for 1 h with HDL 0.5 mg/ml and then stimulated or not with 0.5 mM H2O2 
for 1 h. The effect of the co-incubation of HDL with H2O2 (co-inc) was also tested. ROS production was evaluated 
by fluorescence. Data are expressed as relative fluorescent units (RFU) normalized by the protein concentration of 
total cell lysate, mean ± SD, n = 4. *P < 0.05 vs control, #P < 0.05 vs H2O2-stimulated cells.
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(Fig. 5b). Interestingly, the treatment with HDL alone tended to decrease basal cell proliferation in both PCa 
lines, although the effect was far from statistical significance (LnCaP −14.4% vs untreated cells; PC-3 −14.7% vs 
untreated cells) (Fig. 5). Data were confirmed by MTT assay in both cell lines (not shown).
HDL blunted H2O2-induced shift of cell cycle towards G2/M phase. If compared to untreated cells, 
the exposure of LNCaP to H2O2 for 72 h caused an alteration of cell cycle distribution; in particular, H2O2 caused a 
decrease of cells in the G0/G1 phase (from 60 ± 6% to 51 ± 6%), with a concomitant increase of cells in the G2/M 
phase (from 9 ± 1% to 19 ± 1%) (Fig. 6a). The co-incubation with HDL completely blunted the H2O2-induced 
shift from the G0/G1 towards the G2/M phase (Fig. 6a). PC-3 cells also displayed an increase of cell percentage in 
the G2/M phase from 14 ± 4% to 18 ± 1% after exposure to H2O2 (Fig. 6b). Again, the co-incubation with HDL 
restored the basal cell cycle profile: when compared to H2O2-treated cells, cells in the G2/M phase were reduced 
(6 ± 1%) and those in the G0/G1 phase increased (from 52 ± 5% to 67 ± 7%) (Fig. 6b). HDL prevented the alter-
ations of cell cycle distribution in H2O2-treated PNT2 cells as well (Fig. S4). HDL alone did not affect cell cycle 
profile of LnCaP, PC-3 and PNT2 cells (Fig. 6 and Fig. S4).
Synthetic HDL exert anti-oxidant activity on LNCaP and PC-3 cells. Synthetic HDL consisted in 
a single population of discoidal particles with a diameter of 9.7 nm; unlipidated apoA-I was undetectable at the 
bottom of the gel (Fig. 7a). Based on final weight ratio, each sHDL contained 148 POPC and 2 apoA-I molecules 
per particle.
Synthetic HDL were able to inhibit ROS production when given in combination with H2O2 in both LnCaP 
(−42%) and PC-3 cells (−35%, Fig. 7). sHDL were also effective when given for 1 h and then removed prior to 
H2O2 stimulation; ROS production was indeed reduced by 35% in LNCaP and by 33% in PC-3 cells (Fig. 7).
Unlipidated apoA-I was also tested in both cell lines. In LNCaP, apoA-I was as effective as sHDL, since it 
was able to completely blunt H2O2-induced rise in ROS levels when given before or as co-incubation with the 
pro-oxidant stimulus (Fig. 7b). In PC-3 cells, apoA-I was as effective as sHDL when given as a co-incubation 
with H2O2 (−30.7%). On the contrary, when cells were pre-treated with apoA-I and then stimulated with H2O2, 
ROS levels were reduced by 23.2%, but they were still significantly elevated compared to baseline values (Fig. 7c).
Discussion
We showed for the first time that HDL are able to blunt PCa cell proliferation induced by oxidative stress in vitro. 
In particular, HDL reduced ROS levels in AR-positive and AR-null cellular lines of prostate cancer, thus inhibiting 
ROS-induced cell entry in the G2/M phase. Interestingly, synthetic HDL made of apoA-I and phosphatidylcho-
line fully retained the antioxidant potential of plasma-derived HDL.
The relevance of oxidative stress to PCa development, progression and conversion to a castration-resistant 
phenotype has been demonstrated in vitro and in vivo6. ROS are generated within the cells by mitochondria and 
by extramitochondrial enzymatic systems as NADPH oxidases, and in tumour microenvironment by xenobiotics 
or inflammatory cells9. Interestingly, we first confirmed that PC-3 cells, which resemble the more aggressive PCa 
phenotype, display higher ROS levels than androgen-sensitive and non-tumorigenic ones8; then, we showed that 
short- or long-term exposure to HDL reduced basal oxidative stress in both AR-positive and AR-null cell lines. 
This effect could be relevant to avoid adaptation to oxidative stress-based therapeutics, as radiation21. Indeed, it 
has been described that high levels of ROS can activate the anti-oxidative machinery leading cells to be less sen-
sitive to toxic effects of ROS generated by radiation or other similar therapies; thus, by reducing basal oxidative 
Figure 2. AR activation is not involved in HDL antioxidant effect. LNCaP were treated overnight (o/n) with 
the androgen receptor antagonist bicalutamide (100 nM) before stimulation with 0.5 mM H2O2 for 1 h. HDL at 
0.5 mg/ml were given overnight or as co-incubation with H2O2 (co-inc) for 1 h. ROS production was evaluated 
by fluorescence. Data are expressed as relative fluorescent units (RFU) normalized by the protein concentration 
of total cell lysate, mean ± SD, n = 6. #P < 0.05 vs H2O2-stimulated cells.
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stress of PCa cells, HDL may facilitate the action of stress-based therapies. In addition, the antioxidant poten-
tial of HDL was tested in an extreme condition, as an acute challenge with hydrogen peroxide; we showed that 
HDL were able to limit H2O2-induced oxidative stress and, consequently, oxidative stress-induced proliferation 
in both PCa cells lines. HDL were effective not only when given in combination with the pro-oxidant stimulus 
but also when added before it, even for only 1 h; thus, HDL were able to rapidly modify PCa cells, making them 
more resistant to the following pro-oxidant stimuli. Furthermore, the modulation of the expression of proteins 
involved in the redox balance could be excluded in our experimental setting, since HDL were effective after only 
1 h. The reduction of ROS levels is likely due to (i) HDL protein and lipid components that, acting at cell surface or 
within the cells, are able to directly turn off the oxidative cascade, or (ii) HDL-mediated inhibition of pro-oxidant 
enzymes as NADPH oxidases, whose key role in ROS generation was recently shown in PCa cells22. Of note, HDL 
were effective at concentrations well below their physiological level in plasma; indeed, 0.5 mg/ml of total HDL 
protein roughly corresponds to 40 mg/dl of apoA-I (since it accounts for the 80% of HDL proteins) and 10 mg/dl 
of HDL-cholesterol in plasma23.
The interaction between HDL and membrane transporters/receptors, as the ATP-binding cassette transporters 
A1 and G1 and the scavenger receptor type BI, is a key step in HDL-mediated modulation of cell cholesterol con-
tent, but evidence suggests its involvement in many other atheroprotective activities of HDL24. Thus, the expres-
sion of these transporters and receptors was analysed in the two PCa cell lines compared to non-tumorigenic 
cells. ABCA1 was expressed at very low levels in normal prostate epithelial cells and a further decrease was 
observed in both LNCaP and PC-3 cells; this reduction could be due to the marked hypermethylation at the 
ABCA1 promoter site, as previously shown25. On the contrary, we showed that ABCG1 protein expression was 
markedly upregulated in tumour cell lines, especially in the AR-null one; the mechanisms and the consequences 
of ABCG1 upregulation on the metabolism of PCa cells deserve further investigations. The scavenger receptor 
BI is abundantly expressed in all cell lines at similar levels. However, neither ABCG1 nor SR-BI were involved 
in HDL-mediated antioxidant effect on PCa cells, as shown by silencing experiments. The role of cell cholesterol 
modulation on antioxidant activity of HDL was further excluded by the pre-treatment with LDL or βMCD. The 
lack of SR-BI involvement could be particularly relevant, since its role in tumorigenesis is debated26. Indeed, this 
receptor can facilitate a bidirectional flux of cholesterol between cells and HDL, according to the concentration 
Figure 3. Expression of ABCA1, ABCG1 and SR-BI in prostate cell lines. Protein expression was analyzed by 
western blotting in PNT2, LNCaP and PC-3 cell lines. Results of the densitometric analysis are expressed as fold 
increase of the target/β-actin ratio in tumour cell lines vs PNT2 cells, mean ± SD, n = 7. Representative blots are 
shown at the top. Images have been manipulated to change the original loading sequence LNCaP-PNT2-PC3 
into the more appropriate PNT2-LNCaP-PC3. Images are from the same blots and same exposures. *P < 0.05 vs 
PNT2, #P < 0.05 vs LNCaP.
www.nature.com/scientificreports/
6SCIEntIFIC REPORtS |  (2018) 8:2236  | DOI:10.1038/s41598-018-19568-8
gradient. Indeed, spherical and large discoidal HDL can accept cellular cholesterol through SR-BI; on the con-
trary, cholesteryl esters-rich HDL can become cholesterol donors via this pathway27–29. Thus, SR-BI could favour 
cholesterol uptake by cancer cells and, in addition, the interaction of HDL with SR-BI could activate the PI3K/
Akt and Erk1/2 pathways promoting cell proliferation30. Accordingly, in prostate cancer cells the inhibition of 
SR-BI expression was shown to reduce cell viability31 and a positive correlation was found between elevated SR-BI 
expression and tumour grade, metastasis and poorer patient outcomes32. Experimental evidence suggests that AR 
activation may mediate oxidative stress in PCa cells21,33,34. To address the possible involvement of AR signalling, 
Figure 4. SR-BI and ABCG1 are not involved in HDL antioxidant effect. Panel A, SR-BI and ABCG1 
protein levels in PC-3 cells treated with specific or control (scrambled) siRNA. Image of SR-BI blot has been 
manipulated to eliminate empty lanes between control and SCARB1 siRNA samples and to show 3 bands/
group as the original non manipulated blot for ABCG1. Images come from the same blots and same exposures. 
Original images of SR-BI are reported in Fig. S5. Panel B, ROS levels in H2O2-stimulated PC-3 cells pre-treated 
with specific or control (scrambled) siRNA. The effect of the co-incubation of 0.5 mM H2O2 with 0.5 mg/
ml HDL for 1 h was tested. ROS production was evaluated by fluorescence. Data are expressed as relative 
fluorescent units (RFU) normalized by the protein concentration of total cell lysate, mean ± SD, n = 3. *P < 0.05 
vs control cells incubated with scrambled siRNA, #P < 0.05 vs H2O2-stimulated cells incubated with scrambled 
siRNA, $P < 0.05 vs control cells incubated with ABCG1 or SCARB1 siRNA, §P < 0.05 vs H2O2-stimulated cells 
incubated with ABCG1 or SCARB1 siRNA.
Figure 5. HDL inhibit cell proliferation induced by H2O2 in LNCaP and PC-3 cell lines. LNCaP (Panel a) and 
PC-3 cells (Panel b) were incubated for 72 h with H2O2 5μM, HDL 0.5 mg/ml or with a combination of both. 
Cells were then harvested and counted in a Burker chamber. Data are expressed as mean ± SD, n = 4. *P < 0.05 
vs control, #P < 0.05 vs H2O2-stimulated cells.
www.nature.com/scientificreports/
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the non-steroidal AR antagonist bicalutamide was used; when given overnight to LNCaP cells, bicalutamide did 
not affect the extent of ROS generation by H2O2 or the antioxidant potential of HDL, thus excluding a role of AR 
activation in our experimental setting.
Overall, even if obtained only in two of the several available PCa cells lines, our results provide the rationale 
for investigating the relevance of HDL as a therapeutic tool against prostate cancer. In particular, HDL could have 
a role as adjuvant agents, able to make cancer cells more sensitive to classic cytotoxic molecules. However, the in 
vivo relevance of our findings is unknown; a prostate tumour xenograft model will be needed to address this issue 
and to confirm that HDL are able to affect the proliferation of both androgen-dependent and castration-resistant 
PCa cells. In addition, even if cell cycle analysis did not shown a change in the percentage of apoptotic cells, it is 
not possible to exclude that the decrease of cell number detected after treatment with HDL is due to other effects 
than an inhibition of cell proliferation.
HDL are not suitable for the development as drugs; they are too heterogeneous and their isolation from 
human plasma poses key safety concerns. Synthetic HDL made of the main protein and phospholipid compo-
nents of HDL, namely apoA-I and phosphatidylcholine, were shown to retain most of plasma-derived HDL activ-
ities in vitro and in vivo and are currently in the clinical phase of development as anti-atherosclerotic agents in the 
context of acute coronary syndrome18. These synthetic particles are different from the majority of HDL circulating 
in plasma. First, they display a discoidal and not a spherical shape: discoidal HDL are present in plasma, they 
are nascent particles called preβ-HDL and usually account for the 10–15% of total HDL. Second, their protein 
and lipid composition is very simple and, in particular, they do not contain cholesterol, which is not considered 
responsible for any anti-atherosclerotic effect of HDL17. An advantage of sHDL use is that they are “customizable”, 
as their shape, size and protein/lipid composition can be modulated to achieve maximal effect. For example, if 
particle diameter is kept below 9.6 nm, the interaction with SR-BI could be avoided29. In addition, sHDL particles 
could also be used as carriers of therapeutically relevant molecules to be targeted to cancer cells. We showed 
that sHDL retained the antioxidant capacity of plasma-derived HDL, thus strengthening the idea that sHDL 
could be investigated as adjuvant anti-tumoral agents. Indeed, when used at the same protein concentration, their 
antioxidant potential was equal to that of plasma-derived HDL. However, the actual HDL activity could have 
been underestimated since the isolation process severely reduced the activity of antioxidant enzymes as PON 
and LCAT. ApoA-I was the active component of sHDL, even if protein lipidation was necessary for maximum 
antioxidant effect on PC-3 cells. For a possible therapeutic application, apoA-I lipidation is mandatory to avoid 
rapid renal excretion.
In the present paper, we have analysed HDL effects related to their anti-oxidant properties. However, HDL are 
able to exert a series of effects that could contribute to limit cancer cell proliferation, as their anti-inflammatory 
capacity or their ability to reduce cell cholesterol content15,16. To address these issues is beyond the scope of the 
Figure 6. HDL modulate cell cycle distribution in H2O2-treated cells. LNCaP (Panel a) and PC-3 cells (Panel b)  
were incubated for 72 h with H2O2 5μM, HDL 0.5 mg/ml or with a combination of both. Cells were then 
harvested, stained with propidium iodide and subjected to FACS analysis. Representative histograms of each 
experimental group and cumulative results of the percentage distribution along cell cycle (n = 3) are shown.
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present study and dedicated investigations are ongoing. Other studies evaluated the effect of HDL on different 
cancer cell types including PCa cells with contrasting results. In particular, two studies on PCa cells found an 
increase of proliferation after exposure to HDL31,35. However, differently from our experimental setting, pro-
liferation assays were performed with serum-poor medium, thus it is conceivable that in such condition, HDL 
Figure 7. Synthetic HDL retain the anti-oxidant effect of plasma-derived HDL. Panel a, synthetic HDL particle 
formation and size was verified by native GGE. LNCaP (Panel b) and PC-3 cells (Panel c) were stimulated with 
0.5 mM H2O2 for 1 h. sHDL or apoA-I were tested at 0.5 mg/ml as a pre-treatment of 1 h or as co-incubation 
with H2O2 (co-inc). ROS production was evaluated by fluorescence. Data are expressed as relative fluorescent 
units (RFU) normalized by the protein concentration of total cell lysate, mean ± SD, n = 4. *P < 0.05 vs control, 
#P < 0.05 vs H2O2-stimulated cells.
www.nature.com/scientificreports/
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could represent the only source of cholesterol for almost starved cells, as suggested by Angius et al.36. On the 
contrary, our proliferation experiments were performed with regular growth medium including 5% or 10% FBS 
and no increase of proliferation (or even a slight reduction) was observed in HDL-treated cells not stimulated 
with hydrogen peroxide. Consistently, it has been recently shown that VLDL and LDL, but not HDL, increased 
viability of breast cancer cells maintained in 10% FBS37.
In light of the proposed anti-tumoral role for HDL, it is reasonable to query whether an association between 
plasma levels of HDL-C and the incidence or the progression of PCa exists. Several studies examined the possible 
correlation between HDL levels (measured as plasma levels of HDL-C or of apoA-I, the main protein component 
of HDL) and cancer risk. The issue is still debated since both positive and negative associations were found, likely 
due to the presence of confounding factors as concomitant pathologies and/or therapies; in addition, patients 
with cancer usually display a disease-related reduction of plasma HDL-C. However, there are several indications 
from observational and interventional studies that support the anti-tumoral role of HDL (recently reviewed in38). 
Plasma apoA-I and HDL-C were inversely related to the risk of different types of cancers as ovarian, breast, colon, 
lung and prostate, with a recent meta-analysis showing a 36% risk reduction for every 10 mg/dl increase of plasma 
HDL-C levels39. Consistently, plasma apoA-I levels were included in a FDA-approved test for early stage ovarian 
cancer, together with transthyretin, transferrin, β2-microglobulin and CA12540. To support a causative associa-
tion, human apoA-I transgenic mice displayed reduced lung, melanoma or ovarian tumour development com-
pared to control animals, an effect also observed in mice infused with human apoA-I41,42. As learned from studies 
on their atheroprotective activities, HDL are heterogeneous and different subclasses can display different activ-
ities43. In addition, several physiologic and pathologic conditions can modify HDL composition and function. 
Interestingly, HDL from patients with type 2 diabetes and oxidized HDL, but not control HDL, induced prolifer-
ation of breast cancer cells44,45. Further investigations are required to assess whether cancer itself or anti-tumoral 
therapies may affect HDL functions other than their plasma levels.
Materials and Methods
Lipoproteins. LDL (d = 1.020–1.063 g/ml) and HDL (d = 1.063–1.21 g/ml) were purified by sequential ultra-
centrifugation from the plasma of healthy volunteers46. Total and unesterified cholesterol (TC and UC), triglycer-
ides, phospholipids, apolipoprotein A-I and A-II levels in isolated HDL were determined with standard enzymatic 
or turbidimetric techniques by using a Roche c311 analyzer (Roche Diagnostics, Germany). The cholesteryl ester 
mass was calculated as (TC − UC) × 1.68. HDL composition was expressed as percentage of total HDL mass47. 
LCAT concentration was measured by a specific competitive ELISA developed within our laboratory and LCAT 
activity was evaluated as the ability to esterify cholesterol incorporated into an exogenous standardized sub-
strate, as described48. PON activity was measured as arylesterase activity using phenyl acetate (Sigma-Aldrich, 
Germany) as substrate49. Apolipoprotein A-I was purified from human blood plasma by gel filtration chromatog-
raphy as previously described50.
The study conformed to the guidelines set out in the Declaration of Helsinki and pertinent ethical regu-
lations. The protocol was approved by the ethical committee of Niguarda Hospital (n. 451-092014) and 
all volunteers gave written informed consent for participation in the study. sHDL containing synthetic 
palmitoyl-oleoyl-phosphatidylcholine (POPC, Sigma-Aldrich Chemie GmbH, Germany) and apolipoprotein 
A-I were prepared by the cholate dialysis technique, with a starting POPC:protein weight ratio of 2.17:151. The 
size of sHDL was estimated by nondenaturing gradient gel electrophoresis, using the Pharmacia Phast System52. 
Protein concentration was evaluated by the method of Lowry. HDL and sHDL preparations were dialyzed against 
sterilized saline immediately before use and their concentrations are expressed as protein content.
Cell lines. Experiments were performed using two different human epithelial cell models of prostatic tumour, 
namely LNCaP and PC-3, and the human normal prostate epithelial cell line PNT2. LNCaP are AR positive and 
sensitive and were shown to be tumorigenic in nude mice with a low metastatic potential53. On the contrary, 
PC-3 are AR-null and display an androgen-independent growth; they were shown to be tumorigenic with a high 
angiogenic and metastatic potential in nude mice53. SV40-immortalized PNT2 are non-tumorigenic human pros-
tatic epithelial cells54. Tumour cell lines were purchased from ATCC (VA, USA) and PNT2 were purchased from 
Sigma-Aldrich (Germany); cells were maintained in RPMI 1640 supplemented with 5% (PC-3) or 10% (LNCaP 
and PNT2) fetal bovine serum, 1% penicillin/streptomycin and 2 mM L-glutamine at 37 °C in a humidified 
atmosphere with 5% CO2. Confluent cells were harvested with 0.05% trypsin/0.02% EDTA and seeded in Petri 
dishes or multiwell plates, as indicated below. Cell media, supplements and sterile disposables were purchased 
from EuroClone (Italy).
ROS assay. PNT2, LNCaP and PC-3 cells seeded in 24-well black plates were incubated with HDL, sHDL 
or apoA-I at 0.5 mg/ml up to 16 h in RPMI 1640 (supplemented with 1% bovine serum albumin for LNCaP). 
Cells were then washed with PBS and loaded with 3 μM 2′,7′-dichlorofluorescein (Life Technologies, USA) for 
30 minutes. After RPMI 1640 replenishment, cells were stimulated or not with 0.5 mM H2O2 for 1 h and ROS 
production was measured by fluorescence on a Synergy H1 multi-mode reader equipped with the Gen5 software 
(BioTek, USA). To evaluate the role of AR signalling in ROS generation and HDL antioxidant effect, in separate 
experiments LNCaP were maintained in RPMI 1640 without phenol red and incubated overnight with the AR 
antagonist bicalutamide (100 nM, Sigma-Aldrich). To evaluate the role of cell cholesterol content on HDL antiox-
idant effect, cells were pre-treated overnight with LDL (50 μg/ml) or for 1 h with 2.5 mM beta-methylcyclodextrin 
(βMCD, Sigma Aldrich, Germany).
For each sample, fluorescence was normalized by the protein concentration of the total cell lysate, measured 
by the micro-bicinchoninic acid assay (Thermo Scientific, USA).
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A standard HDL preparation from pooled plasma was tested in each experiment for inter-assay data 
correction.
Cell cholesterol content. Cells were washed with PBS and lysed overnight in 1% sodium cholate and 
10 U/ml DNase (Sigma Aldrich, Germany). Cholesterol was measured by fluorescence using the Amplex Red 
Cholesterol Assay Kit (Sigma Aldrich, Germany), according to the manufacturer instructions55. For each sample, 
cholesterol concentration was normalized by the protein concentration of the total cell lysate, measured by the 
micro-bicinchoninic acid assay.
Western Blotting. PNT-2, LNCaP and PC-3 cells were lysed in 20 mmol/L Tris buffer containing 4% SDS, 
20% glycerol, 1 mmol/L EDTA, 1 mmol/L sodium orthovanadate, 1 mmol/L NaF, 1 μg/mL leupeptin, 1 mmol/L 
benzamidine, 10 μg/mL soy trypsin inhibitor, 1 mmol/L PMSF, and 0.5 mmol/L DTT. Cell debris was removed 
by centrifugation and protein concentration was determined by the micro-bicinchoninic acid assay. Proteins 
were separated by 10% SDS-PAGE and transferred on a nitrocellulose membrane. Membranes were developed 
against ABCA1, ABCG1 and SR-BI (Novus Biologicals, USA), stripped and reprobed with an antibody against 
β-actin (Sigma Aldrich, Germany). Further details are provided in Table S2. Bands were visualized by ECL 
(GE Healthcare Biosciences, Sweden) and band densities were evaluated with a GS-690 Imaging Densitometer 
equipped with the Multi-Analyst software (Bio-Rad Laboratories).
Silencing of SR-BI and ABCG1. PC-3 cells were seeded in 24-well black plates and transfected with 100 
pmol of siRNA against either SR-BI, ABCG1 or noncoding (scrambled) siRNA for 48 h using the OptiMEM/
Lipofectamine 2000 system (Life Technologies, UK), according to the manufacturer’s protocol. siGenome 
ON-TARGETplus SMARTpool were used (Dharmacon, ThermoScientific, USA). Cells were then washed with 
PBS and ROS assay was performed as described above. Silencing efficiency was evaluated by western blotting for 
ABCG1 or SR-BI and β-actin, as described above.
Cell proliferation. LNCaP and PC-3 cells were seeded (300.000 and 100.000 cells/well, respectively) in 6-well 
culture plates in RPMI containing 5–10% FBS (see above). After 48 h cells were moved to RPMI 1640 without 
phenol red containing 5 or 10% charcoal-stripped FBS and allowed to proliferate for additional 48 h. Medium was 
then refreshed and cells were treated for 72 h with saline, 5 µM H2O256, HDL (0.5 mg/mL) or with a combination 
of both. To evaluate the impact of treatments on cell proliferation, cells were harvested and counted by Trypan 
blue exclusion in a Burker chamber. Cell growth was further analysed by the MTT assay (Promega, USA), accord-
ing to manufacturer instructions. After 4 h at 37 °C, absorbance at 570 nm was measured with the Synergy H1 
multi-mode reader equipped with the Gen5 software (BioTek, USA).
Cell cycle analysis. Flow cytometry was used to analyse cell cycle distribution. After trypsinization LNCaP 
and PC3 were re-suspended in 70% cold EtOH (700 μL) and fixed on ice for 15 min. Cells were then centrifuged, 
the pellet was washed with cold PBS Ca2+/Mg2+ and re-suspended in a solution containing 40 μg/mL of RNAse 
and propidium iodide (5 μM). Samples were kept in the dark for 15 min, and the fluorescence of individual nuclei 
was measured. Data acquisition was performed in a NovoCyte flow cytometer (ACEA Biosciences, USA) using 
NovoExpress 1.0.2 software. A minimum of 10,000 events/sample were counted. The number of cells in G0/G1, S, 
and G2/M phases was expressed as percentage of total events.
Statistical analysis. Results are reported as mean and standard deviation (SD). Group differences were eval-
uated by non parametric Kruskal-Wallis and Mann-Whitney tests. The α level of significance was set at 0.05. All 
experiments were performed at least three times using different preparations of HDL or sHDL. Statistical analysis 
was performed using SPSS version 24.0 software (SPSS Inc., Chicago, USA).
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